Cargando…

Overcoming Resistance to HER2 Inhibitors Through State-Specific Kinase Binding

The heterodimeric receptor tyrosine kinase complex formed by HER2 and HER3 can act as an oncogenic driver and is also responsible for rescuing a large number of cancers from a diverse set of targeted therapies. Current inhibitors of these proteins, particularly HER2, have dramatically improved patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novotny, Chris J., Pollari, Sirkku, Park, Jin H., Lemmon, Mark A., Shen, Weijun, Shokat, Kevan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069157/ https://www.ncbi.nlm.nih.gov/pubmed/27595329 http://dx.doi.org/10.1038/nchembio.2171

Ejemplares similares

Structure of the Human Autophagy Initiating Kinase ULK1 in Complex with Potent Inhibitors
por: Lazarus, Michael B., et al.
Publicado: (2014)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Chemical Genetic Analysis of Protein Kinase Cascades
por: Alaimo, Peter J., et al.
Publicado: (2002)

Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
por: Apsel, Beth, et al.
Publicado: (2008)

Dynamic Regulation of a Metabolic Multi-enzyme Complex by Protein Kinase CK2
por: An, Songon, et al.
Publicado: (2010)

Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy
por: Ksionda, Olga, et al.
Publicado: (2018)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
por: Lai, Wei-Yun, et al.
Publicado: (2014)

Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma
por: Lourido, Sebastian, et al.
Publicado: (2010)

Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent
por: Liu, Wei, et al.
Publicado: (2015)

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2022)

The Saccharomyces cerevisiae Mob2p–Cbk1p kinase complex promotes polarized growth and acts with the mitotic exit network to facilitate daughter cell–specific localization of Ace2p transcription factor
por: Weiss, Eric L., et al.
Publicado: (2002)

Drugging the undruggable: Ross Cagan interviews Kevan Shokat
por: Cagan, Ross, et al.
Publicado: (2022)

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
por: Sun, Bowen, et al.
Publicado: (2019)

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors
por: Sonar, Priyanka, et al.
Publicado: (2022)

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
por: De Santis, Sara, et al.
Publicado: (2022)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

Inhibition of ZAP-70 Kinase Activity via an Analog-sensitive Allele Blocks T Cell Receptor and CD28 Superagonist Signaling
por: Levin, Susan E., et al.
Publicado: (2008)

Inhibitor Hijacking of Akt Activation
por: Okuzumi, Tatsuya, et al.
Publicado: (2009)

Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer
por: Park, Soon Young, et al.
Publicado: (2023)

PB1771: OVERCOMING RESISTANCE TO TYROSINE KINASE INHIBITORS IN MYELOID LEUKEMIA CELLS THROUGH ENHANCED FERROPTOSIS
por: Chien, Chih-Fang Chang, et al.
Publicado: (2023)

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy
por: Warkentin, Alexander A, et al.
Publicado: (2014)

A Method for Overcoming Plasma Protein Inhibition of Tyrosine Kinase Inhibitors
por: Young, David J., et al.
Publicado: (2021)

Overcoming Paradoxical Kinase Priming by a Novel MNK1 Inhibitor
por: Bou-Petit, Elisabeth, et al.
Publicado: (2022)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
por: Guiley, Keelan Z., et al.
Publicado: (2023)

Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728
por: Irie, Hiroki, et al.
Publicado: (2020)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2
por: Wang, Bo-Wei, et al.
Publicado: (2021)

A chemical-genetic strategy reveals distinct temporal requirements for SAD-1 kinase in neuronal polarization and synapse formation
por: Kim, Joanne SM, et al.
Publicado: (2008)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

Site-specific incorporation of phosphotyrosine using an expanded genetic code
por: Hoppmann, Christian, et al.
Publicado: (2017)

Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2012)

Harnessing autophagy to overcome mitogen‐activated protein kinase kinase inhibitor‐induced resistance in metastatic melanoma
por: Verykiou, S., et al.
Publicado: (2018)

Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
por: Schlam, Ilana, et al.
Publicado: (2022)

Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
por: Imbert, Caroline, et al.
Publicado: (2020)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jn35dhmnrvnek6lq3ch647jnuu